EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists

Jessalyn J Baljon, Alexander J Kwiatkowski, Hayden M Pagendarm iD, Payton T Stone, Amrendra Kumar, Vijaya Bharti, Jacob A Schulman, Kyle W Becker iD, Eric W Roth, Plamen P Christov, Sebastian Joyce, John T Wilson iD

ACS Nano · 2024-03-05 · 18 (9) · 6845-6862

DOI: 10.1021/acsnano.3c04471 ↗

At a glance

Journal article in ACS Nano, published online on 2024-02-22. Written by Jessalyn J Baljon and 11 co-authors. Institution: Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States. Major MEDLINE topics: Cancer Vaccines, Neoplasms, Nanoparticles. Cited 128 times so far (Crossref); 78 references. The full text is freely available (open access, CC BY 4.0). Funded by: BLRD VA, NIDCR NIH HHS, NIDDK NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Immune checkpoint blockade (ICB) has revolutionized cancer treatment and led to complete and durable responses, but only for a minority of patients. Resistance to ICB can largely be attributed to insufficient number and/or function of antitumor CD8+ T cells in the tumor microenvironment. Neoantigen targeted cancer vaccines can activate and expand the antitumor T cell repertoire, but historically, clinical responses have been poor because immunity against peptide antigens is typically weak, resulting in insufficient activation of CD8+ cytotoxic T cells. Herein, we describe a nanoparticle vaccine platform that can overcome these barriers in several ways. First, the vaccine can be reproducibly formulated using a scalable confined impingement jet mixing method to coload a variety of physicochemically diverse peptide antigens and multiple vaccine adjuvants into pH-responsive, vesicular nanoparticles that are monodisperse and less than 100 nm in diameter. Using this approach, we encapsulated synergistically acting adjuvants, cGAMP and monophosphoryl lipid A (MPLA), into the nanocarrier to induce a robust and tailored innate immune response that increased peptide antigen immunogenicity. We found that incorporating both adjuvants into the nanovaccine synergistically enhanced expression of dendritic cell costimulatory markers, pro-inflammatory cytokine secretion, and peptide antigen cross-presentation. Additionally, the nanoparticle delivery increased lymph node accumulation and uptake of peptide antigen by dendritic cells in the draining lymph node. Consequently, nanoparticle codelivery of peptide antigen, cGAMP, and MPLA enhanced the antigen-specific CD8+ T cell response and delayed tumor growth in several mouse models. Finally, the nanoparticle platform improved the efficacy of ICB immunotherapy in a murine colon carcinoma model. This work establishes a versatile nanoparticle vaccine platform for codelivery of peptide neoantigens and synergistic adjuvants to enhance responses to cancer vaccines.

Subjects

MeSH terms (MEDLINE)

Cancer VaccinesNeoplasmsNanoparticlesHumansAnimalsMiceCD8-Positive T-LymphocytesToll-Like Receptor 4NanovaccinesAntigensPeptidesAdjuvants, ImmunologicImmunotherapyMice, Inbred C57BLTumor Microenvironment

Author keywords

adjuvant synergycancer vaccineendosomal escapeimmune checkpoint blockadeimmunotherapynanoparticle

Substances

Toll-Like Receptor 4NanovaccinesCancer VaccinesAntigensPeptidesAdjuvants, ImmunologicTLR4 protein, human

Authors and institutions

  • Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
  • Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Northwestern University Atomic and Nanoscale Characterization Experimental (NUANCE) Center, Northwestern University, Evanston, Illinois 60208, United States.
  • Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Department of Veteran Affairs Tennessee Valley Healthcare System, Nashville, Tennessee 37212, United States.

ORCID profiles: Hayden M Pagendarm, Kyle W Becker, John T Wilson

Funding

  • BLRD VA
  • NIDCR NIH HHS
  • NIDDK NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • Vanderbilt-Ingram Cancer Center
  • National Cancer Institute

Cite

APA

Baljon, J. J., Kwiatkowski, A. J., Pagendarm, H. M., Stone, P. T., Kumar, A., Bharti, V., Schulman, J. A., Becker, K. W., Roth, E. W., Christov, P. P., Joyce, S., & Wilson, J. T. (2024). A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. ACS Nano, 18(9), 6845-6862. https://doi.org/10.1021/acsnano.3c04471

Vancouver

Baljon JJ, Kwiatkowski AJ, Pagendarm HM, Stone PT, Kumar A, Bharti V, et al. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. ACS Nano. 2024;18(9):6845-6862. doi:10.1021/acsnano.3c04471

BibTeX
@article{Baljon2024,
  author = {Baljon, Jessalyn J and Kwiatkowski, Alexander J and Pagendarm, Hayden M and Stone, Payton T and Kumar, Amrendra and Bharti, Vijaya and Schulman, Jacob A and Becker, Kyle W and Roth, Eric W and Christov, Plamen P and Joyce, Sebastian and Wilson, John T},
  title = {A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {9},
  pages = {6845--6862},
  doi = {10.1021/acsnano.3c04471}
}
Start for free →